Compare AbbVie Inc (ABBV) vs Figs Inc (FIGS) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

FIGS stock trades at $9.90, down 0.9% today, with a mixed technical picture showing a bearish moving average trend but oversold RSI levels. The company reported strong Q1 2026 earnings, beating estimates with 28% revenue growth and raised full-year guidance. Analyst consensus is a Buy with a $18.00 price target, implying significant upside, though valuation ratios like a P/E of 44.91 remain elevated.

The outlook is cautiously optimistic, driven by robust revenue growth, expanding margins, and global expansion. Key risks include cost pressures from tariffs and freight, competitive threats, and the stock's high valuation requiring sustained execution. Near-term performance hinges on Q2 2026 earnings delivery against a $0.07 EPS expectation.